glp-1 and ampk The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice Emerging Frontiers in GLP-1 Therapeutics:

User experimentation suggests that longer initial treatment periods (6+ months continuous) support better benefit retention during subsequent breaks, complete discontinuation breaks of 1-2 months show acceptable benefit maintenance for most users, and very extended breaks (3-6+ months) increase risk of regression toward pre-treatment baseline particularly for short initial treatment courses

However, some individuals, including pre-term infants, cannot make enough and L-carnitine must be supplied in the diet

Do not use if safety seal is broken

Prioritize Protein (Especially at Breakfast) Protein-rich food help us to feel full (Mozzafarian et al 2025